Cite
Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
MLA
Chour, Ali, et al. “Management of Sotorasib-Related Adverse Events and Hepatotoxicities Following Anti-PD-(L)1 Therapy: Experience with Sotorasib in Two French Anti-Cancer Centers and Practical Guidance Proposal.” Lung Cancer (Amsterdam, Netherlands), vol. 191, May 2024, p. 107789. EBSCOhost, https://doi.org/10.1016/j.lungcan.2024.107789.
APA
Chour, A., Basse, C., Lebossé, F., Bonte, P.-E., Girard, N., & Duruisseaux, M. (2024). Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal. Lung Cancer (Amsterdam, Netherlands), 191, 107789. https://doi.org/10.1016/j.lungcan.2024.107789
Chicago
Chour, Ali, Clémence Basse, Fanny Lebossé, Pierre-Emmanuel Bonte, Nicolas Girard, and Michaël Duruisseaux. 2024. “Management of Sotorasib-Related Adverse Events and Hepatotoxicities Following Anti-PD-(L)1 Therapy: Experience with Sotorasib in Two French Anti-Cancer Centers and Practical Guidance Proposal.” Lung Cancer (Amsterdam, Netherlands) 191 (May): 107789. doi:10.1016/j.lungcan.2024.107789.